아시아 태평양 엑소솜 치료제 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

아시아 태평양 엑소솜 치료제 시장 – 2029년까지의 산업 동향 및 예측

  • Medical Devices
  • Published Report
  • Dec 2021
  • Asia-Pacific
  • 350 Pages
  • 테이블 수: 97
  • 그림 수: 49

Asia Pacific Exosome Therapeutic Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2022 –2029
Diagram 시장 규모(기준 연도)
USD 122.59 Thousand
Diagram 시장 규모(예측 연도)
USD 404.38 Thousand
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>아시아 태평양 엑소좀 치료제 시장, 유형별(천연 엑소좀, 하이브리드 엑소좀), 출처(중배엽 줄기 세포, 혈액, 체액, 소변, 수지상 세포, 타액, 우유 및 기타), 치료(면역 요법, 화학 요법 및 유전자 요법), 수송 용량(생체 거대 분자 및 소 분자), 응용 분야(대사 장애, 종양학, 심장 질환, 신경학, 염증 장애, 장기 이식, 산부인과 장애, 혈액 장애 및 기타), 투여 경로(비경구 및 경구), 최종 사용자(연구 및 학술 기관, 병원 및 진단 센터), 국가(한국, 호주, 홍콩, 아시아 태평양의 나머지 지역) 산업 동향 및 2029년까지의 예측

아시아 태평양 엑소좀 치료제 시장시장 분석 및 통찰력: 아시아 태평양 엑소솜 치료제 시장

 아시아 태평양 엑소좀 치료제 시장은 2022년부터 2029년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년부터 2029년까지의 예측 기간 동안 16.4%의 CAGR로 성장하고 있으며 2021년의 122.59천 달러에서 2029년까지 404.38천 달러에 도달할 것으로 예상된다고 분석했습니다. 만성 염증성 자가면역 질환의 유병률 증가와 엑소좀 치료제의 기술 개발은 예측 기간 동안 시장 수요를 견인하는 주요 요인으로 작용할 가능성이 높습니다.

엑소좀은 엔도솜으로 구성된 세포 유래 세포외 소포의 특정 종류이며 일반적으로 직경이 30~150nm로 가장 작은 유형의 세포외 소포입니다. 지질 이중층으로 보호되는 엑소좀은 원래 세포에서 유래한 복잡한 내용물이 들어 있는 세포외 환경으로 밀려납니다. 이 내용물에는 단백질, 지질, 메신저 리보핵산(mRNA), 미세소체 리보핵산(miRNA), 데옥시리보핵산(DNA)이 들어 있습니다. 엑소좀은 다중 소포체가 융합하여 세포외 공간으로 배출되는 방식으로 형성됩니다. 엑소좀은 자가면역 질환과 같은 다양한 만성 질환을 치료하는 데 사용되었습니다. 나노기술은 엑소좀과 같은 나노캐리어를 기반으로 암을 사전에 감지하는 데 새로운 통찰력을 보여주었습니다. 엑소좀은 치료적 개입에 적용할 수 있는 강력한 잠재력을 제공하므로, 엑소좀은 잠재적인 약물 운반체로 간주되어 왔습니다.

엑소좀은 두 가지 유형으로 구성되어 있습니다. 자연 엑소좀과 하이브리드 엑소좀입니다. 자연 엑소좀은 외인성 엑소좀과 자가 엑소좀으로 더 세분화됩니다. 자가 엑소좀은 암, 자가면역 질환 및 만성 염증성 질환의 치료를 위한 약물의 표적 전달을 위한 안전하고 효과적인 운반체입니다. 외인성 엑소좀은 다양한 세포의 엔도솜에서 방출되는 작은 세포외막 소포이며 활액액, 양수 및 정액과 같은 대부분의 체액에서 발견될 수 있습니다. 암에서 엑소좀은 전이성 확산, 약물 내성 및 새로운 혈관 형성에 중요한 역할을 합니다.

아시아 태평양 엑소좀 치료제 시장 성장을 담당하는 주요 요인은 만성 염증성 질환의 증가, 엑소좀 치료제에 대한 연구 개발 활동의 증가, 엑소좀 치료제의 개발 및 생산을 위한 정부 자금 지원입니다. 또한 신흥 경제권에서 엑소좀 치료제의 성장 잠재력과 항노화 요법의 사용 증가는 엑소좀 치료제 시장 성장을 뒷받침합니다. 그러나 비용 증가, 엄격한 규제, 엑소좀 치료제 사용 시 관찰되는 위험은 시장 성장을 방해할 수 있는 제약입니다. 의료비 지출 증가는 시장 성장에 수익성 있는 기회를 제공할 것으로 예상됩니다. 반면, 투자 증가와 엑소좀을 분리하기 위한 표준화된 절차의 부족, 필요한 전문 지식의 부족은 시장 성장에 영향을 미칠 것으로 예상되는 중요한 과제 중 일부입니다.

아시아 태평양 엑소좀 치료제 시장 보고서는 시장 점유율, 새로운 개발 및 국내 및 지역 시장 참여자의 영향에 대한 세부 정보를 제공하고, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서 기회를 분석합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 당사에 문의하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.

아시아 태평양 엑소좀 치료제 시장아시아 태평양 엑소솜 치료제 시장 범위 및 시장 규모

아시아 태평양 엑소좀 치료제 시장은 유형, 출처, 치료법, 운송 용량, 응용 분야, 투여 경로 및 최종 사용자를 기준으로 7개의 주요 세그먼트로 분류됩니다.

  • 유형을 기준으로, 아시아 태평양 엑소좀 치료제 시장은 천연 엑소좀과 하이브리드 엑소좀으로 세분화됩니다. 2022년에는 천연 엑소좀 세그먼트가 엑소좀의 천연 소재와 약물 전달의 이점으로 인해 아시아 태평양 엑소좀 치료제 시장을 지배할 것으로 예상됩니다.
  • On the basis of source, the Asia-Pacific exosome therapeutics market is segmented into mesenchymal stem cells, blood, body fluids, urine, dendritic cells, saliva, milk, and others. In 2022, the mesenchymal stem cell segment is expected to dominate the Asia-Pacific exosome therapeutics market due to emerging applications of mesenchymal stem cells and expansion of pipeline, availability, and ease of harvesting.
  • On the basis of therapy, the Asia-Pacific exosome therapeutics market is segmented into immunotherapy, gene therapy, and chemotherapy. In 2022, the immunotherapy segment is expected to dominate the Asia-Pacific exosome therapeutics market due to ease of convenience, high accuracy, and improvement in the long-term survival rate.
  • On the basis of transporting capacity, the Asia-Pacific exosome therapeutics market is segmented into bio macromolecules and small molecules. In 2022, the bio macromolecules segment is expected to dominate the Asia-Pacific exosome therapeutics market due to the presence of high sensitivity, increased use of protein therapeutics to cure inflammatory disorders, and boosting the natural defenses in the body to combat inflammatory diseases.
  • On the basis of application, the Asia-Pacific exosome therapeutics market is segmented into metabolic disorders, oncology, cardiac disorders, neurology, inflammatory disorders, organ transplantation, gynecology disorders, blood disorders, and others. In 2022, the metabolic disorders segment is expected to dominate the Asia-Pacific exosome therapeutics market due to the increase in cases of metabolic disorders in China and India and the availability of exosome therapeutics in diagnostic laboratories.
  • On the basis of route of administration, the Asia-Pacific exosome therapeutics market is segmented into parenteral and oral. In 2022, the parenteral segment is expected to dominate the Asia-Pacific exosome therapeutics market due to enhanced bioavailability and immediate onset of action.
  • On the basis of end user, the Asia-Pacific exosome therapeutics market is segmented into research and academic institutes, hospitals, and diagnostics centers. In 2022, the research and academic institutes segment is expected to dominate the Asia-Pacific exosome therapeutics market due to the rise in research and development of exosomes in Japan and support from the government in funding.

Asia-Pacific Exosome Therapeutics Market Country Level Analysis

Asia-Pacific exosome therapeutics market is analyzed, and market size information is provided by type, source, therapy, transporting capacity, application, route of administration, and end user.

The countries covered in the exosome therapeutics market report are Japan, China, India, South Korea, Australia, Singapore, Indonesia, the Philippines, and rest of Asia-Pacific.

Asia-Pacific is expected to grow with the highest CAGR in the forecast periods as in the Asia-Pacific's countries demand exosome therapeutics products is increasing very rapidly with the urbanization and laboratory automation. China is expected to dominate in the market in the Asia-Pacific market as China is one of the leading countries to inculcate the exosome therapeutics market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

The Growth Potential For Exosome Therapeutics In Emerging Economies And The Strategic Initiatives By Market Players Are Creating New Opportunities In The Asia-Pacific Exosome Therapeutics Market 

 Asia Pacific exosome therapeutics market also provides you with detailed market analysis for every country's growth in a particular industry with exosome therapeutics sales, the impact of advancement in the exosome therapeutics, and changes in regulatory scenarios with their support for the exosome therapeutics market. The data is available for the historic period 2011 to 2020.

Competitive Landscape and Asia Pacific Exosome Therapeutics Market Share Analysis

 Asia Pacific exosome therapeutics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the exosome therapeutics market.

The major company providing Asia- Pacific exosome therapeutics is Exopharm.

DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The strategic initiatives by market players along with new technological advancements for exosome therapeutics are bridging the gap for the treatment of chronic autoimmune diseases.

For instance,

  • 2021년 9월 Exopharm은 엑소좀 치료제에 LEAP 기술을 사용하기 위해 일본의 Showa Denko Materials와 협력했습니다. LEAP 기술은 암과 같은 질병에 대한 재생 의학으로 사용되는 엑소좀 생산 중에 직면하는 주요 문제를 줄입니다. 이 협력은 요코하마 재생 의학 사업부 내에서 Exopharm의 LEAP(리간드 기반 엑소좀 친화성 정제) 기술 플랫폼을 평가할 것입니다. 그 결과 Showa Denko Materials는 Exopharm의 엑소좀 기술을 활용하게 될 것입니다.

시장 참여자들의 협력, 합작투자 및 기타 전략은 엑소좀 치료 시장에서 기업 시장을 확대하고 있으며, 이를 통해 기업이 엑소좀 치료 시장에 대한 제공 서비스를 개선하는 데에도 도움이 됩니다.

 

 


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA PACIFIC EXOSOME THERAPEUTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 PIPELINE ANALYSIS

6 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING PREVALENCE OF CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE, LYME DISEASE, AND OTHER CHRONIC DEGENERATIVE DISEASES

7.1.2 RISE IN INCIDENCE OF ONCOLOGY DISEASES

7.1.3 TECHNOLOGICAL ADVANCEMENTS IN EXOSOME THERAPEUTICS

7.1.4 RISE IN RESEARCH AND DEVELOPMENT ACTIVITIES, INVOLVED IN EXOSOME THERAPEUTICS

7.1.5 GOVERNMENT FUNDING FOR THE DEVELOPMENT AND PRODUCTION OF EXOSOME THERAPEUTICS

7.2 RESTRAINTS

7.2.1 HIGH COST ASSOCIATED WITH THE EXOSOME THERAPEUTICS

7.2.2 LACK OF AUTHENTICATION REQUIREMENTS FOR ISOLATION OF EXOSOMES

7.2.3 RISKS OBSERVED WHILE USING EXOSOME THERAPEUTICS

7.2.4 UNMET MEDICAL NEEDS

7.3 OPPORTUNITIES

7.3.1 INCREASE USE OF ANTI-AGING THERAPY

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.3 RISE IN HEALTHCARE EXPENDITURE

7.3.4 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES

7.3.5 PROGRESSING THERAPEUTIC VALUE OF EXOSOME

7.4 CHALLENGES

7.4.1 THE SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE ISOLATION OF EXOSOME

7.4.2 LATE APPROVAL ASSOCIATED WITH PRODUCT LAUNCHES

8 IMPACT OF COVID-19 ON ASIA PACIFIC EXOSOME THERAPEUTICS MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC DECISIONS BY MANUFACTURERS

8.5 CONCLUSION

9 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY TYPE

9.1 OVERVIEW

9.2 NATURAL EXOSOMES

9.2.1 AUTOLOGOUS EXOSOMES

9.2.2 EXOGENOUS EXOSOMES

9.3 HYBRID EXOSOMES

10 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY SOURCE

10.1 OVERVIEW

10.2 MESENCHYMAL STEM CELLS

10.3 BLOOD

10.3.1 T-LYMPHOCYTES

10.3.2 OTHERS

10.4 BODY FLUIDS

10.4.1 AMNIOTIC FLUID

10.4.2 SEMEN

10.4.3 SYNOVIAL FLUID

10.4.4 OTHERS

10.5 URINE

10.6 DENDRITIC CELLS

10.7 SALIVA

10.8 MILK

10.9 OTHERS

11 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY THERAPY

11.1 OVERVIEW

11.2 IMMUNOTHERAPY

11.3 GENE THERAPY

11.4 CHEMOTHERAPY

12 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY

12.1 OVERVIEW

12.2 BIO MACROMOLECULES

12.2.1 NUCLEIC ACIDS

12.2.2 PROTEINS

12.2.3 PEPTIDES

12.3 SMALL MOLECULES

13 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY APPLICATION

13.1 OVERVIEW

13.2 METABOLIC DISORDERS

13.3 ONCOLOGY

13.3.1 NON-SMALL CELL LUNG CANCER

13.3.2 BREAST CANCER

13.3.3 GASTRIC CANCER

13.3.4 HEAD AND NECK CANCER

13.3.5 OTHERS

13.4 CARDIAC DISORDERS

13.5 NEUROLOGY

13.5.1 ALZHEIMER'S DISEASE

13.5.2 PARKINSON'S DISEASE

13.5.3 OTHERS

13.6 INFLAMMATORY DISORDERS

13.7 ORGAN TRANSPLANTATION

13.8 GYNECOLOGY DISORDERS

13.9 BLOOD DISORDERS

13.1 OTHERS

14 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 PARENTERAL

14.3 ORAL

15 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY END USER

15.1 OVERVIEW

15.2 RESEARCH AND ACADEMIC INSTITUTES

15.3 HOSPITALS

15.4 DIAGNOSTIC CENTERS

16 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY REGION

16.1 ASIA-PACIFIC

16.1.1 SOUTH KOREA

16.1.2 AUSTRALIA

16.1.3 HONG-KONG

16.1.4 REST OF ASIA-PACIFIC

17 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

18 COMPANY PROFILE

18.1 KIMERA LABS

18.1.1 COMPANY SNAPSHOT

18.1.2 COMPANY SHARE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENTS

18.2 STEM CELLS GROUP

18.2.1 COMPANY SNAPSHOT

18.2.2 COMPANY SHARE ANALYSIS

18.2.3 PRODUCT PORTFOLIO

18.2.4 RECENT DEVELOPMENTS

18.3 AEGLE THERAPEUTICS

18.3.1 COMPANY SNAPSHOT

18.3.2 PRODUCT PORTFOLIO

18.3.3 RECENT DEVELOPMENTS

18.4 AVALON GLOBOCARE CORP.(2021)

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 PRODUCT PORTFOLIO

18.4.4 RECENT DEVELOPMENTS

18.5 CAPRICOR THERAPEUTICS (2021)

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENTS

18.6 CODIAK (2021)

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENTS

18.7 EXOSOME SCIENCES (A SUBSIDIARY OF AETHLON MEDICAL) (2021)

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS NO RECENT DEVELOPMENTS

18.8 EXOPHARM

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENTS

18.9 EVOX THERAPEUTICS

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENTS

18.1 EV THERAPEUTICS

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENTS

18.11 JAZZ PHARMACEUTICALS, INC

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 RENEURON GROUP PLC

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 STEM CELL MEDICINE

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

표 목록

TABLE 1 ASIA PACIFIC EXOSOME THERAPEUTICSMARKET, PIPELINE ANALYSIS

TABLE 2 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 3 ASIA PACIFIC NATURAL EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4 ASIA PACIFIC NATURAL EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 5 ASIA PACIFIC HYBRID EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 6 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 7 ASIA PACIFIC MESENCHYMAL STEM CELLS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 8 ASIA PACIFIC BLOOD IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 9 ASIA PACIFIC BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 10 ASIA PACIFIC BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 11 ASIA PACIFIC BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 12 ASIA PACIFIC URINE IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 13 ASIA PACIFIC DENDRITIC CELLS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 14 ASIA PACIFIC SALIVA IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 15 ASIA PACIFIC MILK IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 16 ASIA PACIFIC OTHERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 17 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)

TABLE 18 ASIA PACIFIC IMMUNOTHERAPY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 19 ASIA PACIFIC GENE THERAPY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 20 ASIA PACIFIC CHEMOTHERAPY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 21 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 22 ASIA PACIFIC BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23 ASIA PACIFIC BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 24 ASIA PACIFIC SMALL MOLECULES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 25 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 26 ASIA PACIFIC METABOLIC DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 27 ASIA PACIFIC ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 28 ASIA PACIFIC ONCOLOGY IN ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 29 ASIA PACIFIC CARDIAC DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 30 ASIA PACIFIC NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31 ASIA PACIFIC NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 32 ASIA PACIFIC INFLAMMATORY DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33 ASIA PACIFIC ORGAN TRANSPLANTATION IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 34 ASIA PACIFIC GYNECOLOGY DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35 ASIA PACIFIC BLOOD DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 36 ASIA PACIFIC OTHERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 38 ASIA PACIFIC PARENTERAL IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 39 ASIA PACIFIC ORAL IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 41 ASIA PACIFIC RESEARCH AND ACADEMIC INSTITUTES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42 ASIA PACIFIC HOSPITALS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 43 ASIA PACIFIC DIAGNOSTIC CENTERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2019-2029 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC NATURAL EXOSOME IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 55 ASIA-PACIFIC NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 56 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 57 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 58 SOUTH KOREA EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 59 SOUTH KOREA NATURAL EXOSOME IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 60 SOUTH KOREA EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 61 SOUTH KOREA BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 62 SOUTH KOREA BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 63 SOUTH KOREA EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)

TABLE 64 SOUTH KOREA EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 65 SOUTH KOREA BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 66 SOUTH KOREA EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 67 SOUTH KOREA ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 68 SOUTH KOREA NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 69 SOUTH KOREA EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 70 SOUTH KOREA EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 71 AUSTRALIA EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 72 AUSTRALIA NATURAL EXOSOME IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 73 AUSTRALIA EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 74 AUSTRALIA BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 75 AUSTRALIA BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 76 AUSTRALIA EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)

TABLE 77 AUSTRALIA EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 78 AUSTRALIA BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 79 AUSTRALIA EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 80 AUSTRALIA ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 81 AUSTRALIA NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 82 AUSTRALIA EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 83 AUSTRALIA EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 84 HONG-KONG EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 85 HONG-KONG NATURAL EXOSOME IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 86 HONG-KONG EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 87 HONG-KONG BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 88 HONG-KONG BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 89 HONG-KONG EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)

TABLE 90 HONG-KONG EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 91 HONG-KONG BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 92 HONG-KONG EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 93 HONG-KONG ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 94 HONG-KONG NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 95 HONG-KONG EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 96 HONG-KONG EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 97 REST OF ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

그림 목록

FIGURE 1 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: DBMR POSITION GRID

FIGURE 8 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: END USER COVERAGE GRID

FIGURE 10 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: SEGMENTATION

FIGURE 11 THE INCREASED PREVALENCE OF AUTOIMMUNE DISORDERS, LYME DISEASES, INCIDENCE OF CANCER AND RISE IN TECHNOLOGICAL ADVANCEMENTS IS EXPECTED TO DRIVE THE ASIA PACIFIC EXOSOME THERAPEUTICS MARKET FROM 2022 TO 2029

FIGURE 12 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE ASIA PACIFIC EXOSOME THERAPEUTICS MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC EXOSOME THERAPEUTICS MARKET

FIGURE 14 THE PREVALENCE OF MULTIPLE SCLEROSIS IN WORLD HEALTH ORGANISATION (WHO) REGIONS IN 2020.

FIGURE 15 INCIDENCE RATE OF CANCER IN AUSTRALIA AND OTHER COUNTRIES (2020)

FIGURE 16 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY TYPE, 2021

FIGURE 17 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY TYPE, 2020-2029 (USD THOUSAND)

FIGURE 18 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY SOURCE, 2021

FIGURE 21 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY SOURCE, 2020-2029 (USD THOUSAND)

FIGURE 22 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY SOURCE, CAGR (2022-2029)

FIGURE 23 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY SOURCE, LIFELINE CURVE

FIGURE 24 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY THERAPY, 2021

FIGURE 25 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY THERAPY, 2020-2029 (USD THOUSAND)

FIGURE 26 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY THERAPY, CAGR (2022-2029)

FIGURE 27 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY THERAPY, LIFELINE CURVE

FIGURE 28 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, 2021

FIGURE 29 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

FIGURE 30 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, CAGR (2022-2029)

FIGURE 31 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, LIFELINE CURVE

FIGURE 32 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY APPLICATION, 2021

FIGURE 33 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY APPLICATION, 2020-2029 (USD THOUSAND)

FIGURE 34 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 35 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 36 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 37 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

FIGURE 38 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 39 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 40 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY END USER, 2021

FIGURE 41 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY END USER, 2020-2029 (USD THOUSAND)

FIGURE 42 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 43 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET: SNAPSHOT (2021)

FIGURE 45 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET: BY COUNTRY (2021)

FIGURE 46 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 47 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 48 ASIA-PACIFIC EXOSOME THERAPEUTICS MARKET: BY TYPE (2022-2029)

FIGURE 49 ASIA PACIFIC EXOSOME THERAPEUTICS MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Asia Pacific Exosome Therapeutics Market is projected to grow at a CAGR of 16.4% during the forecast period by 2029.
The future market value of the Asia Pacific Exosome Therapeutics Market is expected to reach USD 404.38 thousand by 2029.
The major players in the Asia Pacific Exosome Therapeutics Market is Exopharm.
The countries covered in the Asia Pacific Exosome Therapeutics Market are Japan, China, India, South Korea, Australia, Singapore, Indonesia, the Philippines, and rest of Asia-Pacific.